SFA Therapeutics Analysis
What is SFA Therapeutics?
SFA Therapeutics is developing oral deuterated short-chain fatty acid drugs for inflammatory and oncology indications. Its lead program, SFA-002, is in Phase 1b for plaque psoriasis, and the pipeline also includes programs for pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease. The company reports 18 granted patents, New Chemical Entity status, and over 100 human exposures across its SFA platform.
Location
610 Old York Rd, Jenkintown, Pennsylvania 19046, United States
Employees
1-10
Founded
2016
Revenue
$1.1-1.4M
Business Model
Revenue generated through funding rounds, grants, and future drug sales.
Product Features & Capabilities
- autoimmune disease treatments (psoriasis, rheumatoid arthritis, uveitis, bullous pemphigoid), cancer therapies (hepatocellular carcinoma, pancreatic cancer, myeloid leukemias), infectious disease solutions (post-viral inflammatory complications), liver disease treatments (fibrosis, MASH/NASH), anti-inflammatory adjuvants for CAR-T therapies
Who are the founders of SFA Therapeutics
Competitors Overview
SFA Therapeutics operates in a competitive landscape with several notable companies focusing on similar therapeutic areas. The main competitors identified are:
-
Odyssey Therapeutics
- Focus: Odyssey is dedicated to transforming the standard of care for patients with autoimmune and inflammatory conditions. They develop small-molecule drugs targeting the innate immune system, which is crucial for managing autoimmune diseases and cancer.
- Advantages: Odyssey has a strong emphasis on precision medicine, aiming to create therapies that specifically target disease pathology. They have secured significant funding, which supports their robust pipeline of immunomodulators.
-
Nimbus Therapeutics
- Focus: Nimbus has a diverse portfolio that includes programs for cancer, autoimmune conditions, and metabolic diseases. They are known for their innovative drug design and development processes.
- Advantages: Nimbus has a strong financial backing and a pipeline that includes both clinical and preclinical programs. They focus on developing highly selective therapeutics, such as allosteric inhibitors, which may offer improved efficacy and safety profiles compared to traditional therapies.
-
Escient Pharmaceuticals
- Focus: While specific details on Escient's current pipeline were not retrieved, they are known to be involved in developing therapies for autoimmune diseases and cancer.
- Advantages: Escient's approach often includes leveraging novel biological pathways, which may provide unique treatment options in the competitive landscape.
These competitors differ from SFA Therapeutics primarily in their specific therapeutic targets, drug development strategies, and the technologies they employ. SFA Therapeutics leverages the human gut microbiome and biosynthetic molecules, which may offer unique advantages in modulating immune responses compared to the more traditional approaches of its competitors.
Investors
- Y Combinator
- Acequia Capital
- 10 other unnamed investors
Market Focus
SFA Therapeutics primarily focuses on the biotechnology industry, specifically in developing drugs for autoimmune diseases, chronic inflammatory diseases, and cancer by utilizing the human gut microbiome and biosynthetic molecules.
See something that needs updating? Suggest edits to this profile.